Originally published on 6/21/2017 at Pharma's Almanac
Driving Molecules to Market
UPM’s seven-acre Bristol, TN headquarters houses over 450,000 square feet of commercial-scale manufacturing space, which means we have the capacity to handle these types of molecules, regardless of volume or scale. Leveraging dedicated facility space and equipment, we were able to develop and bring to market the only two oral peptides currently on the market.
Flexibility in Service
Because we are a private, family-owned business, we can make decisions rapidly, and without having to go through a corporate bureaucracy. This flexibility affords us the ability to take onboard clients with various situations, and to facilitate the development of the products they believe in.
Advancing Formulation Development Efforts
UPM has a rich history as an R&D company. Our experience enables us to anticipate what we think our customers may need, and to identify gaps based on just preliminary discussion. UPM has worked with every type of company—from virtual to big pharma—and has a proven track record of adapting to the requirements of both to optimize their chances of success.
Promoting Transparency Through Effective Project Management
At UPM, your project manager is your on-site advocate as well as your scientist. Our goal is to function with complete transparency, so we employ an instant communication system, updating our clients as their projects progress. Because the owners of UPM have been on both sides of the fence, both as a finished product pharma company and now a CDMO, they have an in-depth understanding of what is needed and will never call a client with a problem without offering solutions.
Limiting Future Manufacturing Constraints
UPM bought into a facility with great capacity to create flexibility and options for clients. We have significant warehouse space to store raw materials, and have plenty of room for expansion to meet clients’ needs. UPM specializes in small molecule, oral solid dose and semi solid products, low humidity suites, and has significant infrastructure for controlled drug substance manufacturing and storage as well as scalability from concept to commercialization for tablets, capsules and semi-solid products.